Wellcome Sanger Institute
The UK genome institute whose Cancer Genome Project found the BRAF mutation in melanoma, built COSMIC and defined mutational signatures.
Founded in 1992 to sequence the human genome, the Wellcome Sanger Institute launched the Cancer Genome Project under Michael Stratton in 2000. It reported the BRAF V600E mutation in melanoma in 2002, created the COSMIC catalogue of somatic mutations, defined the mutational signatures framework with Ludmil Alexandrov in 2013, and with the Broad Institute built the cancer dependency map and Genomics of Drug Sensitivity in Cancer resources led by Mathew Garnett. Sanger co-founded Open Targets with EMBL-EBI and industry partners and the Human Cell Atlas, and leads the Mutographs Grand Challenge on cancer causes. Its tools underpin much of modern tumour sequencing and target discovery.
- Cancer Genome Project
- COSMIC
- Mutational signatures (Mutographs)
- Cancer dependency map and GDSC
- Open Targets
- Human Cell Atlas
Pages like this
not linked directly; found by shared links- IdeaAn open foundation model of the cancer cell trained on perturbation data
Shares CZ CELLxGENE / Human Cell Atlas, DepMap (Cancer Dependency Map), Broad Institute of MIT and Harvard, CRISPR functional genomics.
- IdeaA drug screen that only rewards killing sleeping cancer cells
Shares DepMap (Cancer Dependency Map), Functional (ex vivo) drug testing, CRISPR functional genomics, Patient-derived organoids.
- InstitutionMax Delbrück Center for Molecular Medicine
Shares CZ CELLxGENE / Human Cell Atlas, CRISPR functional genomics, Single-cell & spatial profiling, Melanoma.
- Key paperDefining a Cancer Dependency Map: which genes each cancer cell line cannot live without
Shares DepMap (Cancer Dependency Map), Broad Institute of MIT and Harvard, Functional (ex vivo) drug testing, CRISPR functional genomics.
- IdeaAn open model of every cancer cell state, built from perturbation atlases
Shares Broad Institute of MIT and Harvard, CRISPR functional genomics, Single-cell & spatial profiling, Patient-derived organoids.
- IdeaA public atlas of drug-pair responses across a thousand patient-derived organoids
Shares DepMap (Cancer Dependency Map), Functional (ex vivo) drug testing, Patient-derived organoids, Whole-exome & whole-genome sequencing.
- PersonGad Getz
Shares Mutational signature, Broad Institute of MIT and Harvard, Whole-exome & whole-genome sequencing.
- InstitutionWellcome
Shares Mutational signature, Single-cell & spatial profiling, Whole-exome & whole-genome sequencing, Cancer Research UK.